Anokion is harnessing the power of natural immune equilibrium to develop solutions for antigen-specific immune tolerance.
Anokion has raised $35.0M in total funding. The most recent round was Venture - Series Unknown. The last funding was announced in October 2022.
Anokion's investors include Versant Ventures, Novartis Venture Fund, Celgene, Novo Ventures, Foundation for Innovation and Technology (FIT).
Anokion is headquartered in Ecublens, Switzerland.
Anokion is harnessing the power of natural immune equilibrium to develop solutions for antigen-specific immune tolerance.
Anokion is at the Venture - Series Unknown stage.
Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated .
"Anokion — Funding & Investors." VCBacked, October 18, 2022, https://www.vcbacked.co/company/anokion. Accessed September 30, 2026.
VCBacked. (2022). Anokion — Funding & Investors. Retrieved September 30, 2026, from https://www.vcbacked.co/company/anokion
{{cite web |title=Anokion — Funding & Investors |url=https://www.vcbacked.co/company/anokion |website=VCBacked |access-date=September 30, 2026}}Profile data sourced and verified per the VCbacked methodology · Last funding round dated